Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) chairman Gabriele Cerrone tells Proactive London's Andrew Scott they're planning to spin out its StemPrintER and SPARE genomics-based personalised medicine businesses as a separate stock market quoted company. Cerrone says Tiziana shareholders will benefit from holding shares in both Tiziana, which has a rapidly developing drug portfolio, while also realising the standalone value of the StemPrintER operation as it progresses through its own development milestones.
Tiziana Life Sciences to spin out StemPrintER to 'maximise its value'
